Pleasant Prairie, WI, United States of America

Michael L Curtin

This inventor holds 21 USPTO granted patents and 15 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in Kinase Inhibitors. Top assignees: Abbvie Inc., Abbott Laboratories Corporation, Abbyie Inc.. Active years: 1996-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael L Curtin. Retrieved from https://idiyas.com/inventor/michael-l-curtin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 15)

% Patents Active = 85.7

CIPO Patents = 3 (Patent Applications = 12)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 7.8

ph-index = 6

Forward Citations = 279(Granted Patents)

Location History:

Lindenhurst, IL (US) (1996)
Kenosha, WI (US) (1999)
Pleasant Prairie, WI (US) (2001 - 2018)

Company Filing History:

Abbott Laboratories Corporation

Years Active: 1996-2018

Loading Chart...

Areas of Expertise:

EED Inhibitors

Pyrrolo Pyridine

NAMPT Inhibitors

Kinase Inhibitors

Thienopyridine

CYP Safety Profile

Pyrimidine Inhibitors

Matrix Metalloproteinases

Reverse Hydroxamate

C-terminal Ketone

Platelet Activating Factor

Thieno Pyridine

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9957274 - Indane inhibitors of EED and methods of their use (2018-05-01),

2. 9796708 - Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors (2017-10-24),

3. 9758511 - NAMPT inhibitors (2017-09-12),

4. 9334264 - NAMPT inhibitors (2016-05-10),

5. 9302989 - NAMPT and rock inhibitors (2016-04-05),

6. 9296723 - NAMPT inhibitors (2016-03-29),

7. 9193723 - NAMPT inhibitors (2015-11-24),

8. 9187472 - NAMPT inhibitors (2015-11-17),

9. 8975398 - NAMPT inhibitors (2015-03-10),

10. 8722890 - Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile (2014-05-13),

11. 8637529 - [object Object] (2014-01-28),

12. 8436179 - Kinase inhibitor with improved solubility profile (2013-05-07),

13. 8426408 - Pyrimidine inhibitors of kinases (2013-04-23),

14. 8273736 - Thienopyridine and furopyridine kinase inhibitors (2012-09-25),

15. 7737160 - Thienopyridine and furopyridine kinase inhibitors (2010-06-15),

Title: Innovation and Impact: The Contributions of Michael L. Curtin

Introduction

Michael L. Curtin, based in Pleasant Prairie, Wisconsin, has made significant strides in the field of pharmaceuticals, with a remarkable portfolio of 21 patents. His work primarily focuses on developing innovative compounds that advance treatment options for various diseases, particularly cancer.

Latest Patents

Curtin’s latest patents highlight his commitment to addressing serious health conditions. Among these, he has developed indane inhibitors of EED, encompassing compounds with specific structural formulas aimed at treating EED-related diseases, including various forms of cancer. In addition, he has contributed to the field with his patent on pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors, which detail compounds to be used as therapeutic agents against cancer. These patents not only present novel pharmaceutical compositions but also provide methods for utilizing these compounds effectively.

Career Highlights

Throughout his career, Curtin has contributed to significant advancements while working at esteemed organizations such as AbbVie Inc. and Abbott Laboratories Corporation. His affiliations with these companies have allowed him to collaborate on pioneering research and development projects that aim to improve healthcare outcomes.

Collaborations

Curtin has worked closely with notable colleagues, including Michael Michaelides and Howard Robin Heyman. These collaborations have enriched his research and fostered a shared commitment to innovation in the pharmaceutical industry.

Conclusion

Michael L. Curtin's inventive spirit and dedication to advancing medical treatments are reflected in his extensive patent portfolio. His contributions, particularly in the realm of cancer therapies, exemplify the potential of innovation in transforming healthcare and improving patient lives.

Profile summary based on public USPTO records.